Avalon Pharmaceuticals, Inc.
Officials from Avalon Pharmaceuticals, Inc., detail the latest developments
Published in Lab Law Weekly, August 17th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Avalon Pharmaceuticals, Inc.
Report 1: Avalon Pharmaceuticals, Inc. (NASDAQ:AVRX), announced continued positive interim results from its Phase I study of AVN944, for the treatment of hematologic malignancies in elderly and refractory patients. Interim data indicate AVN944 is well tolerated, has dose-dependent pharmacokinetics, induces biomarkers of programmed cell death in cancer cells from patients, and demonstrates stabilized disease in almost half of the patients after...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2007-08-17)
More Articles from Lab Law Weekly
- Abbey Spanier Rodd & Abrams, Llp
Abbey Spanier Rodd & Abrams, LLP Announces Class Action Securities Fraud Suit on Behalf of Health Management Associates, Inc. Investors - Aging
National Conference on Medical, Legal and Ethical Issues of Eldercare - Angiology
Fujitsu and BizTech Healthcare Solutions Protect Patients From Identity Theft and Insurance Fraud - Asbestos Disease Awareness Organization
ADAO Applauds Unanimous Passage of Senator Patty Murray's Ban Asbestos in America Act by U.S. Senate Committee on Environment and Public Works - Bally Total Fitness
Bally Total Fitness Announces Noteholder Acceptance of Prepackaged Plan of Reorganization - Bally Total Fitness Holding Corporation
Bally Total Fitness Obtains Favorable First Day Rulings - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
